Skip to content

Lung Cancer Treatments and Mutations

Most cited papers

  1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine · 2004 · 11,565 citations
  2. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine · 2016 · 10,276 citations
  3. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 9,473 citations
  4. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience · 2004 · 9,452 citations
  5. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 8,551 citations
  6. Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine · 2009 · 8,355 citations
  7. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience · 2015 · 7,918 citations
  8. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations
  9. Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations
  10. Comprehensive molecular profiling of lung adenocarcinomaNature · 2014 · 5,803 citations
  11. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine · 2006 · 5,796 citations
  12. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 5,640 citations
  13. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine · 2010 · 5,571 citations
  14. Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine · 2005 · 5,451 citations
  15. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2002 · 5,254 citations
  16. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 4,715 citations
  17. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience · 2007 · 4,559 citations
  18. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine · 2010 · 4,480 citations
  19. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences · 2004 · 4,371 citations

Metadata from OpenAlex (CC0).